ID
33874
Beskrivning
Study ID:103860/269 Clinical Study ID:103860/269 (HBV-269) Study Title: Phase II study to evaluate the immunogenicity of GSK Biologicals' preservative-free Engerix-B and thiomersal-free Engerix-B vaccines compared to Engerix™-B and evaluate safety and reactogenicity of each vaccine when administered intramuscularly according to a 0, 1, 6 month schedule in healthy volunteers Patient Level Data:Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: Hepatitis B Vaccine, Recombinant Trade Name: Engerix-B Study Indication: Hepatitis B
Nyckelord
Versioner (1)
- 2019-01-05 2019-01-05 -
Rättsinnehavare
GlaxoSmithKline
Uppladdad den
5 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Immunogenicity, safety and reactogenicity of preservative-free Engerix-B and thiomersal-free Engerix-B vaccines compared to Engerix™️-B
Study Conclusion
- StudyEvent: ODM
Beskrivning
Investigator Signature
Alias
- UMLS CUI-1
- C2346576
Beskrivning
I certify that I have reviewed the data in this case report form, the Adverse Events and Serious Adverse Event sections including any laboratory data (if appropriate) and that all information is complete and accurate.
Datatyp
date
Alias
- UMLS CUI [1,1]
- C2346576
- UMLS CUI [1,2]
- C0011008
Beskrivning
Investigator Signature
Datatyp
text
Alias
- UMLS CUI [1]
- C2346576
Similar models
Study Conclusion
- StudyEvent: ODM
C0008972 (UMLS CUI-2)
C0805701 (UMLS CUI [1,2])
C1706839 (UMLS CUI [1,2])
C1710677 (UMLS CUI [1,2])
C0805839 (UMLS CUI [1,2])
C0805839 (UMLS CUI [1,2])
C1142435 (UMLS CUI [1,3])
C0011008 (UMLS CUI [1,2])